Deciphering the Cell Senescence Code to Improve Healthspan – S-ENCODE

We have combined several OMICs technologies including transcriptomics, epigenomics, and metabolomics and integrated the generated data sets using our bioinformatic pipeline. We have used biochemical and molecular biology approaches to dissect the role pericentromeric heterochromatin in senescence.

The consortium published the first epigenomic senescence clock including a hierarchical transcription factor (TF) network and novel types of enhancers that control senescence in human fibroblasts. We demonstrated that interfering with TF function in senescence has therapeutic potential in cancer therapy. We extended these seminal findings to other senescence inducers and cell types establishing a pan-senescence biomarker gene signature. We also completed the epigenomic and metabolomic analysis of different senescence inducers identifying a number of common metabolites that may play a critical role in senescence establishment. Another important finding was that pericentromeric heterochromatin is specifically dismantled at senescence onset in a p53-dependent manner, challenging our understanding of the heterochromatin changes occurring at senescence and the current view that p53 behaves as a genome guardian.

The consortium will now move on to integrate transcriptomes and epigenomes from cells induced into senescence by different stressors and in different cell-types to provide a pan-senescence gene-regulatory signature that will inform on therapeutic interventions. Finally, transcriptome, epigenome and metabolome will be integrated as well towards the same end. To study the mitochondrial alterations during senescence we will tag the mitochondrial outer membrane with a molecular beacon to purify them by immunoprecipitation and study their function in senescenc. We will also study the mechanisms by which the downregulation of TRF2 upregulates the expression of subtelomeric genes and triggers mitochondrial dysfunction. Finally, we envision to start the first senotherapies in age-related diseases.

1. Augereau A, Mariotti M, Pousse M, Filipponi D, Libert F, Beck B, Gorbunova V, Gilson E, Gladyshev VN. Sci Adv. 2021 Feb 19;7(8):eabe0174. doi: 10.1126/sciadv.abe0174.
2. Martínez-Zamudio RI, Roux PF, Freitas JANLF, Robinson L, Doré G, Sun B, Gil J, Herbig U, and Bischof O (2020). Nature Cell Biology 22(7): 842-855. doi: 10.1038/s41556-020-0529-5.
3. Müller-Deubert S, Ege C, Krug M, Meißner-Weigl J, Rudert M, Bischof O, Jakob F, Ebert R (2020) Stem Cells International :7865484. doi: 10.1155/2020/7865484.
4. Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, Gil J, Hara E, Krizhanovsky V, Jurk D, Maier AB, Narita M, Niedernhofer L, Passos JF, Robbins PD, Schmitt CA, Sedivy J, Vougas K, von Zglinicki T, Zhou D, Serrano M, Demaria M. Cell 179(4):813-827. doi: 10.1016/j.cell.2019.10.005.
5. Frasca D, Bou Saada Y, Garcia D, Friguet B. Mech Ageing Dev. 2021 Mar;194:111428. doi: 10.1016/j.mad.2020.111428.
6. Hamon MP, Ahmed EK, Baraibar MA, Friguet B. Proteomics. 2020 Mar;20(5-6): . doi: 10.1002/pmic.201800421. Epub 2019 Oct 15. PMID: 31507063
7. Cohen AA, Kennedy BK, Anglas U, Bronikowski AM, Deelen J, Dufour F, Ferbeyre G, Ferrucci L, Franceschi C, Frasca D, Friguet B, Gaudreau P, Gladyshev VN, Gonos ES, Gorbunova V, Gut P, Ivanchenko M, Legault V, Lemaître JF, Liontis T, Liu GH, Liu M, Maier AB, Nóbrega OT, Olde Rikkert MGM, Pawelec G, Rheault S, Senior AM, Simm A, Soo S, Traa A, Ukraintseva S, Vanhaelen Q, Van Raamsdonk JM, Witkowski JM, Yashin AI, Ziman R, Fülöp T. Mech Ageing Dev. 2020 Oct;191:111316. doi: 10.1016/j.mad.2020.111316.

Chronological age is the most important individual risk factor for the development of many chronic diseases and cancers (hereafter designed as age-related diseases), accounting for the majority of societal morbidity, mortality, and public health costs. The common pathophysiological mechanisms underlying age-related diseases are poorly understood, impeding the development of rational therapeutic interventions to prevent and treat these diseases and maximize healthy aging. Recent findings strongly suggest that changes in common basic cell-autonomous and non-autonomous processes play a critical role in aging. Importantly, these common aging pathways can be altered in diseases as diverse as neurodegeneration, cardiovascular disorders, chronic obstructive pulmonary disease (COPD), osteoarthritis, diabetes to name a few. Intervening into such a fundamental process to prevent multiple diseases simultaneously, rather than treating age-related diseases individually, as is current practice, would transform modern medicine in causative and economical way. There is a growing consensus that the accumulation of senescent cells in tissues is a common aging process contributing to age-related diseases. Senescence is a cellular response to nonlethal genotoxic and oncogenic stress that results in a permanent cell cycle arrest. Cellular senescence is a double-edged sword process playing beneficial roles during embryogenesis, wound healing, and tumor suppression while contributing to age-related diseases. Consistently, senescent cells are enriched in the affected tissues of these diseases. Regarding cancer, senescence can be induced by oncogenic activation behaving as an intrinsic onco-suppressive mechanism while the accumulation of senescent stromal cells creates fertile soil for carcinoma development. Importantly, senescent cell elimination in animals prevents the appearance of age-related diseases. However, there are still many unresolved questions before to envisage anti-senescence therapies as to the clock and cell-type specificity of the senescence program, the interplay between different senescence inducers such as telomere shortening, oxidative stress and oncogenic activation, to what extent senescence drives age-related diseases, how senescent cells can be recognized in affected tissues and selectively targeted for elimination and whether such elimination would prevent or treat age-related diseases.
To address these issues, we propose the program S-ENCODE to comprehensively identify the clocks driving the senescence program of different types of cells using a time-resolved, multi-layered, integrative profiling approach.
The realization of S-ENCODE will reveal the key molecular programs underlying cellular senescence and thus will pave the way to the development of innovative strategies for the specific detection, reprogramming and elimination of senescent cells in age-related pathologies using small molecules or genetic interventions. Within S-ENCODE, four prominent senescence and aging research groups will join forces in an interdisciplinary endeavor that brings together scientists with unique expertise, skills, technologies and highly visible contributions to the field of aging in the past. We anticipate that accomplishing these objectives will lay the foundation for a new biomedical research and technology field implicating reprogramming of senescence clocks to prevent and treat age-related diseases.